Palisade Bio (NASDAQ:PALI) Upgraded at Wall Street Zen

Palisade Bio (NASDAQ:PALI) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research firms have also recently weighed in on PALI. Citigroup reaffirmed a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Piper Sandler assumed coverage on shares of Palisade Bio in a research report on Monday. They set an “overweight” rating and a $25.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Palisade Bio Price Performance

PALI opened at $2.50 on Friday. The business has a 50 day simple moving average of $2.01 and a 200-day simple moving average of $1.32. The stock has a market capitalization of $372.50 million, a P/E ratio of -1.18 and a beta of 1.43. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). Research analysts anticipate that Palisade Bio will post -12.43 EPS for the current year.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.